eligibility_summary
Adults ≥18 with pathology‑confirmed advanced/metastatic solid tumors (escalation: no standard options, expansion: untreated). Must have ≥1 extracranial measurable lesion (RECIST), tissue available, ECOG 0–1, life expectancy ≥12 wks, contraception, not pregnant. Exclude prior B7‑H3, recent anticancer therapy/RT/major surgery, intolerance to PD‑L1/cetuximab/enzalutamide/platinums, significant marrow/organ/CV dysfunction or severe disease, active infection/bleeding, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06332170 (ARTEMIS-101) tests combinations built around HS-20093, a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3 (CD276) highly expressed on solid tumors. Mechanism: HS-20093 binds B7-H3 on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor-cell death (ADC, potential Fc effector activity). Combinations: • Adebrelimab: anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor) blocking PD-1/PD-L1 to restore T-cell activity in the tumor microenvironment. • Cetuximab: anti-EGFR IgG1 mAb inhibiting EGFR signaling and mediating ADCC against EGFR-expressing tumor cells. • Cisplatin/Carboplatin: platinum chemotherapies that form DNA crosslinks, triggering apoptosis. • Enzalutamide: small-molecule androgen receptor (AR) inhibitor blocking AR signaling. Targeted cells/pathways: B7-H3–positive tumor cells, PD-L1/PD-1 axis on tumor/immune cells, EGFR pathway, DNA replication/repair, AR-driven signaling.